$501 Million is the total value of Aisling Capital Management LP's 21 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BBIO | BridgeBio Pharma Inc. (BBIO) | $284,413,000 | -23.1% | 6,068,125 | 0.0% | 56.72% | -4.2% | |
| GLUE | Monte Rosa Therapeutics Inc. (GLUE) | $32,804,000 | -1.8% | 1,472,331 | 0.0% | 6.54% | +22.2% | |
| NUVB | Nuvation Bio Inc. (NUVB) | $25,258,000 | +6.8% | 2,541,009 | 0.0% | 5.04% | +33.0% | |
| HRMY | Sell | Harmony Biosciences Holdings Inc. (HRMY) | $22,723,000 | -4.5% | 592,815 | -29.7% | 4.53% | +19.0% |
| ELEV | Elevation Oncology Inc. (ELEV) | $22,084,000 | -42.6% | 2,834,910 | 0.0% | 4.40% | -28.5% | |
| SNDX | Syndax Pharmaceuticals, Inc. (SNDX) | $19,588,000 | +11.3% | 1,025,000 | 0.0% | 3.91% | +38.6% | |
| AGLE | Aeglea Biotherapeutics Inc. (AGLE) | $13,445,000 | +14.2% | 1,691,151 | 0.0% | 2.68% | +42.3% | |
| ACRS | Aclaris Theraputics Inc. (ACRS) | $11,420,000 | +2.5% | 634,455 | 0.0% | 2.28% | +27.6% | |
| BMEA | Biomea Fusion Inc. (BMEA) | $9,561,000 | -23.3% | 798,757 | 0.0% | 1.91% | -4.5% | |
| TALS | Talaris Therapeutics Inc. (TALS) | $9,260,000 | -7.7% | 682,923 | 0.0% | 1.85% | +15.0% | |
| PSTX | Poseida Therapeutics Inc. (PSTX) | $7,605,000 | -27.3% | 1,043,267 | 0.0% | 1.52% | -9.4% | |
| VRNA | Verona Pharma plc (VRNA)sponsored ads | $7,302,000 | -16.2% | 1,332,485 | 0.0% | 1.46% | +4.4% | |
| SPRB | Spruce Biosciences, Inc. (SPRB) | $7,245,000 | -46.4% | 1,205,511 | 0.0% | 1.44% | -33.2% | |
| RPHM | Reneo Pharmaceuticals Inc. (RPHM) | $6,601,000 | -20.2% | 886,075 | 0.0% | 1.32% | -0.6% | |
| AVRO | AVROBIO, Inc. (AVRO) | $5,635,000 | -37.2% | 1,009,779 | 0.0% | 1.12% | -21.8% | |
| MRKR | Marker Therapeutics, Inc. (MRKR) | $5,311,000 | -39.4% | 3,142,857 | 0.0% | 1.06% | -24.6% | |
| OBSV | ObsEva SA (OBSV) | $4,312,000 | +2.6% | 1,386,338 | 0.0% | 0.86% | +27.8% | |
| BCEL | Atreca Inc. (BCEL) | $2,415,000 | -26.9% | 387,653 | 0.0% | 0.48% | -8.9% | |
| VIRX | Viracta Therapeutics Inc. (VIRX) | $2,314,000 | -29.3% | 288,571 | 0.0% | 0.46% | -12.0% | |
| ZSAN | Zosano Pharma Corporation (ZSAN) | $1,956,000 | -24.3% | 2,718,226 | 0.0% | 0.39% | -5.8% | |
| Nabriva Therapeutics plc (NBRV) | $227,000 | -12.0% | 191,028 | 0.0% | 0.04% | +9.8% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-11-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Verona Pharma plc (VRNA) | 20 | Q3 2023 | 23.0% |
| AVROBIO, Inc. (AVRO) | 20 | Q3 2023 | 13.6% |
| Aclaris Theraputics Inc. (ACRS) | 20 | Q3 2023 | 6.6% |
| Aeglea Biotherapeutics Inc. (AGLE) | 19 | Q2 2023 | 7.5% |
| BridgeBio Pharma Inc. (BBIO) | 18 | Q3 2023 | 67.3% |
| Marker Therapeutics, Inc. (MRKR) | 18 | Q1 2023 | 11.7% |
| Atreca Inc. (BCEL) | 18 | Q3 2023 | 3.1% |
| Syndax Pharmaceuticals, Inc. (SNDX) | 15 | Q3 2023 | 17.2% |
| Zosano Pharma Corporation (ZSAN) | 15 | Q2 2022 | 5.8% |
| ObsEva SA (OBSV) | 14 | Q1 2022 | 18.5% |
View Aisling Capital Management LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-07 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-09 |
| 13F-HR | 2023-02-09 |
| 13F-HR | 2022-11-03 |
| 13F-HR | 2022-08-10 |
| 13F-HR | 2022-05-10 |
| 13F-HR | 2022-02-18 |
| 13F-HR | 2021-11-12 |
View Aisling Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.